✦ LIBER ✦

Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme

✍ Scribed by Sylvia Haas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management consensus guidance for the us

✍ Turpie, A. G. G.; Kreutz, R.; Llau, J.; Norrving, B.; Haas, S. 📂 Article 📅 2012 🏛 Schattauer 🌐 English ⚖ 382 KB

Rivaroxaban (BAY 59-7939) – an oral, dir

✍ Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Michael Zuehlsdorf 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

Effect of hepatic impairment on the phar

✍ Kubitza, Dagmar; Roth, Angelika; Becka, Michael; Alatrach, Abir; Halabi, Atef; H 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Treatment of Proximal Deep-Vein Thrombos

✍ G. Agnelli; A. Gallus; S.Z. Goldhaber 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 34 KB

Rivaroxaban-an oral, direct Factor Xa in

✍ Jay R. Lieberman; Nadia Rosencher; Frank Misselwitz 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 20 KB

Dose-escalation study of rivaroxaban (BA

✍ Bengt I. Eriksson; Lars C. Borris; Ola E. Dahl; Sylvia Haas; Menno V. Huisman; A 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 302 KB